In short
This article discusses an 18-month clinical trial investigating the effectiveness of Eftrenonacog Alfa (ALPROLIX) in improving joint health for patients with hemophilia A and B. The study aims to assess joint outcomes using ultrasound technology, clinical evaluations, and patient-reported measures. This low-intervention trial provides valuable insights into the long-term effects of ALPROLIX on joint health and quality of life for individuals with hemophilia.
At a glance
- Study Type
- 18-month low-intervention prospective, multicentre study
- Participants
- Patients with hemophilia A or B on prophylaxis with Eftrenonacog Alfa (ALPROLIX)
- Primary Objective
- Evaluate overall joint status using ultrasound (US)
- Secondary Objectives
- Assess specific joint changes, clinical joint status, target joints, bleeding episodes, quality of life
- Assessment Methods
- HEAD-US, HJHS, bleeding episode tracking, PROMIS, IPAQ-SF
- Drug Information
- ALPROLIX (Eftrenonacog Alfa), available in 250, 500, 1000, 2000, and 3000 IU strengths
- Administration
- Injection, maximum daily dose 100 IU/kg
- Study Duration
- 18 months with assessments at baseline, 6, 12, and 18 months
What is Eftrenonacog Alfa?
Eftrenonacog alfa is a medication used to treat hemophilia B, a rare bleeding disorder. It is also known by several other names, including: Recombinant fusion protein consisting of human coagulation factor IX attached to the Fc domain of human IgG1 BIIB-029 rFIXFc Coagulation factor IX (recombinant), Fc fusion protein The brand name for this medication is Alprolix.
Medical Conditions Treated
Eftrenonacog alfa is specifically designed to treat hemophilia B, also known as factor IX deficiency. Hemophilia B is a genetic disorder that affects the blood's ability to clot properly. People with this condition lack sufficient levels of clotting factor IX, which can lead to prolonged bleeding after injuries, surgeries, or even spontaneously.
How It Works
Eftrenonacog alfa works by replacing the missing or deficient factor IX in patients with hemophilia B. It is a recombinant fusion protein, which means it's artificially created in a laboratory. The medication combines factor IX with a part of an antibody (the Fc domain of human IgG1). This fusion allows the medication to last longer in the body, potentially reducing the frequency of injections needed.
Administration and Dosage
Eftrenonacog alfa is administered as an injection. It comes in various strengths, including 250 IU, 500 IU, 1000 IU, 2000 IU, and 3000 IU, all provided as a powder and solvent for solution for injection. The specific dosage depends on the patient's condition, weight, and doctor's recommendation. The maximum daily dose is typically 100 IU/kg (international units per kilogram of body weight).
Clinical Study Overview
A clinical study called JOIN-us is currently underway to assess the effectiveness of eftrenonacog alfa in treating hemophilia B. This 18-month study aims to evaluate joint health in patients using this medication for prophylaxis (preventive treatment).
The main objective of the study is to assess overall joint status using ultrasound in patients treated with eftrenonacog alfa over the 18-month period. Secondary objectives include evaluating specific aspects of joint health, such as: Synovium (joint lining) thickness Cartilage condition Bone damage Clinical joint status using a standardized score (Hemophilia Joint Health Score) Presence and development of target joints (joints that bleed frequently) Bleeding episodes Quality of life
Benefits and Effectiveness
The study aims to measure the effectiveness of eftrenonacog alfa through several key outcomes: Changes in joint health as measured by ultrasound and clinical examination Reduction in the number of bleeding episodes, particularly in joints Improvement in physical function and reduction in pain Overall improvement in quality of life These outcomes will be assessed at various time points throughout the 18-month study period.
Patient Eligibility
To be eligible for treatment with eftrenonacog alfa, patients typically need to meet certain criteria: Diagnosed with hemophilia B At least 6 months of documented pre-study treatment data Previous treatment with any marketed recombinant or plasma-derived factor IX concentrate for at least 6 months No presence of factor IX inhibitors (antibodies that can interfere with treatment) Not currently enrolled in other interventional clinical studies It's important to note that the final decision on eligibility should always be made by a healthcare professional.
Quality of Life Impact
The JOIN-us study also aims to evaluate the impact of eftrenonacog alfa on patients' quality of life. This includes assessing: Physical function and activity levels Pain intensity and interference with daily life Overall health-related quality of life These aspects are measured using standardized questionnaires at the beginning and end of the study period.